Market Spotlight
AstraZeneca Stock Analysis: What the Latest AZN Results Mean for Investors
AstraZeneca's Q3 2026 Core EPS of $2.79 beat consensus and the shares closed about 7% higher — but full-year guidance was reconfirmed, not raised.
Jack Green·2 Nov 2026